Parmax Pharma EGM clears capital raise via preferential shares and warrants
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Parmax Pharma held its 2nd EGM on July 2, 2026 via video conferencing. Members approved four items: (1) increase in authorised share capital and amendment to the capital clause of the MOA, (2) adoption of a new set of articles of association, (3) preferential issue of 31,37,586 equity shares to non-promoters, and (4) preferential issue of 21,45,145 convertible warrants to non-promoters. Voting was via remote e-voting from June 29 to July 1, 2026 and during the meeting. Scrutinizer report and voting results will be filed separately.
Non-promoter share and warrant issuance will dilute existing shareholders. Higher authorised capital and new articles enable further fundraising.